Atrium Therapeutics (NASDAQ:RNA) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of $(1.10) by 11.82 percent. This is a 7.78 percent decrease over losses of $(0.90) per share from the same period last year. The company reported quarterly sales of $19.635 million which beat the analyst consensus estimate of $2.000 million by 881.75 percent. This is a 1.15K percent increase over sales of $1.573 million the same period last year.